Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MNK-1411 in boys aged 4–8 years with Duchenne muscular dystrophy
2017-004139-35Phase 2Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Mar 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing MNK-1411 with Placebo (2 arms). Primary endpoint: Change from baseline in 10 meter walk/run time. Started Mar 2018; status: terminated.
02
Drugs
MNK-1411
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2017-004139-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004139-35.